RFK Jr. expands FDA advisory panel with pro-peptide members amidst FDA opposition

Advisory Panel Changes

Robert F. Kennedy Jr., a critic of vaccine policies, has reshaped an FDA advisory panel by adding nine members who advocate for peptide use, raising the total number of advisors to 13. This change coincides with Kennedy's agenda to challenge the FDA's current stance against these injectable peptide drugs.

The newly appointed members primarily have financial connections to wellness clinics promoting peptide therapies, which raises questions about conflicts of interest within the panel.

FDA's Position on Peptides

Earlier in 2023, FDA scientists concluded that the peptide drugs lack adequate evidence proving their benefits and may present safety hazards. Despite these findings, Kennedy is pushing for a reevaluation of the FDA's restrictive policies on these drugs.

Upcoming Meetings and Discussions

The advisory panel's meetings are scheduled for July 23 and 24, where the focus will be on several peptides, including BPC-157 and emideltide, among others. A portion of these meetings will determine if these peptides should be available for compounding pharmacies to produce, which currently they are not allowed to do for human use.

The discussions will revolve around the safety and efficacy of each peptide, despite the FDA's consistent warning against their use based on research capacity.

Regulatory Concerns

Kennedy's efforts to stack the panel with pro-peptide advocates increase the likelihood of the advisory committee siding with the interests of peptide promoters. This shift poses significant implications for future regulatory practices and public health, particularly regarding the approval of unproven therapies.